恩杂鲁胺和帕博利珠单抗作为转移性尿路上皮癌新的一线标准治疗方案。
Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.
作者信息
Zhu Xiaolin, Koshkin Vadim S
机构信息
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
出版信息
Med. 2024 Feb 9;5(2):106-108. doi: 10.1016/j.medj.2023.11.010. Epub 2023 Dec 20.
Treatment options for patients with metastatic urothelial carcinoma ineligible for cisplatin-based chemotherapy have historically been limited. O'Donnell et al. recently reported the results of EV-103 Cohort K, leading to accelerated approval of enfortumab vedotin and pembrolizumab for cisplatin-ineligible patients and raising additional questions of how to best utilize this effective regimen.
对于不符合基于顺铂化疗条件的转移性尿路上皮癌患者，以往的治疗选择一直有限。奥唐纳等人最近报告了EV-103队列K的结果，促使恩沃利单抗和帕博利珠单抗加速获批用于不符合顺铂治疗条件的患者，并引发了关于如何最佳使用这一有效治疗方案的更多问题。
Zotero 插件